Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Phase 1
15
about 1.9 years
18+
1 site in CA
About this study
This trial is testing the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). Mezigdomide may extend the time CAR T cells persist in the body in relapsed multiple myeloma.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Mezigdomide
- 2.Undergo Biospecimen Collection
- 3.Undergo Bone Marrow Aspiration
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Incidence of adverse events
Secondary: Complete response rate, Duration of response, Overall response rate, Overall survival, Progression free survival, Time to progression
diagnostic, biopsy, imaging
Oncology